erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.. however, bentley also warned that these treatments can be hazardous as they may cause bleeding which becomes more likely as the amount of svd increases..